Boni, C., Andre, T., Banzi, M.C., Hickish, T. F., Tabernero, J., Clingan, P., Chibaudel, B. and De Gramont, A., 2009. Similarities and differences between the adjuvant oxaliplatin-based trials, MOSAIC and NSABP C-07. Current Colorectal Cancer Reports, 5 (3), pp. 166-170.
Full text not available from this repository.
Based on the results of the MOSAIC trial that were recently confi rmed by the NSABP protocol C-07 study, the combination of oxaliplatin and 5-fl uorouracil has become the standard adjuvant treatment for patients with stage III colon cancer. These pivotal studies confi rm a similar, signifi cant advantage in populations with stage II and III disease; however, they show a remarkable difference in toxicity, with greater risk of life-threatening complications (eg, diarrhea and bowel wall injury) in the NSABP C-07 trial. In this article, we analyze the differences and similarities between these studies.
|Subjects:||Technology > Medicine and Health > Medicine and Surgery|
|Group:||School of Health and Social Care > Centre for Postgraduate Medical Research and Education|
|Deposited By:||Professor Tamas F. Hickish|
|Deposited On:||09 Sep 2010 18:15|
|Last Modified:||07 Mar 2013 15:36|
|Repository Staff Only -|
|BU Staff Only -|
|Help Guide -||Editing Your Items in BURO|